Navigation Links
Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
Date:8/5/2008

- Phase IIb study examines efficacy and safety of once-daily TMC278 in

treatment-naive adults with HIV-1 -

MEXICO CITY, Aug. 5 /PRNewswire/ -- New phase IIb data from Tibotec Pharmaceuticals Ltd. provides additional information on the safety and efficacy of TMC278, the company's once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), as part of HIV combination therapy in treatment-naive adults. These findings were presented today at the International AIDS Conference (AIDS 2008) in Mexico City.

Seventy-six percent of patients receiving the 25 mg dose of TMC278, which is being studied in phase III trials, achieved an undetectable viral load (<50 HIV-1 RNA copies/mL) at week 96 compared with 71 percent of patients receiving efavirenz (EFV). Of patients receiving the 75 mg and 150 mg doses of TMC278, 72 percent and 71 percent achieved an undetectable viral load, respectively.

"NNRTIs have been an integral part of combination antiretroviral therapy for over a decade," said clinical trial investigator Peter Shalit, M.D. Swedish Medical Center, Seattle, WA. "The phase IIb data show potential for TMC278 as a once-daily treatment option for patients who have not previously taken anti-HIV medications."

TMC278 is an investigational product, and the safety and efficacy of it, in combination with other antiretroviral agents, has not been established. Two major phase III trials for TMC278 are being conducted in Africa, Asia, Europe, North America and South America, and are currently recruiting treatment-naive adult patients.

Study Design

The phase IIb dose-finding study (TMC278-C204) evaluated the efficacy, tolerability and safety of once-daily TMC278 at three blinded doses (25 mg, 75 mg, and 150 mg) and included an open label EFV 600 mg arm. A total of 368 patients were randomised to receive one of the three doses of TMC278 or EFV, and all patients received a background regimen of t
'/>"/>

SOURCE Tibotec Pharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
2. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
5. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
6. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
9. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
10. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
11. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... --  Quest Diagnostics (NYSE: DGX ), ... celebrates a decade on the North America Dow Jones ... World DJSI. The Dow Jones Sustainability ... economic, environmental and social criteria. To be included or ... sustainability initiatives. "A sustainable business is a ...
(Date:9/12/2014)... 12, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... focused on chronic inflammatory disease and neurologic disorders, ... from the U.S. Food and Drug Administration (FDA) ... (NDIN) for the formulations of Anatabloc® and CigRx® submitted ... indicated that the FDA considers anatabine citrate, a principal ...
(Date:9/11/2014)... Fla. , Sept. 11, 2014 ... cancer-treatment research and development firm, has discovered substances ... sediment samples that were recovered from the ocean ... and Recovery Limited Partnership. Logo - ... exciting as the discovery of Gold Rush-era treasure ...
Breaking Medicine Technology:Quest Diagnostics Marks 10 Years on the Dow Jones Sustainability Index 2Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response 2Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response 3Odyssey Marine Exploration and Morphogenesis discover biotech 'treasures' in the deep 2Odyssey Marine Exploration and Morphogenesis discover biotech 'treasures' in the deep 3
(Date:9/15/2014)... September 15, 2014 Stem cells are ... and can divide (through mitosis) to produce more stem ... of cardiovascular diseases, leukemia (a kind of hematological system ... kidney and other parenchymal organs, etc. , Currently, cord ... amid stem cell upstream sectors and even the whole ...
(Date:9/15/2014)... In addition to hosting, Stone Chiropractic ... Chair massages will be offered by Katherine Smith LLMT, ... homemade jams and muffins. Elaine Bauman from Beauty ... teach about doTERRA Essential Oils while Amira Watters will ... from face-painting to a coloring table and more. ...
(Date:9/15/2014)... 15, 2014 Ticketability.com can offer online customers ... Toyota Center, and Smoothie King Center. Fans are happy to ... first headlining tour in a period of three years. , ... 2014 concerts at Ticketability.com. , Colorado concertgoers who reside in ... 1st Bank Center. Texas fans have two chances to see ...
(Date:9/15/2014)... 2014 Recently, Top 10 Best ... compared many web hosting companies and announced that ... best suppliers for webmasters from all over the ... hosting plan. The company’s approach to hosting is ... accessible and powerful enough for anyone to use. ...
(Date:9/15/2014)... With a simple swab of the cheek, ... insight to help personalize the treatment for patients with vascular ... ideal approach to medicine is preventive care. But, it can ... will respond to specific drugs. A simple cheek swab test ... the physician to tailor medical therapy and optimize outcomes. , ...
Breaking Medicine News(10 mins):Health News:Global and China Stem Cell Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:Global and China Stem Cell Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:Global and China Stem Cell Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:Stone Chiropractic Brings Local Businesses Together for a Community Fall Festival 2Health News:Stone Chiropractic Brings Local Businesses Together for a Community Fall Festival 3Health News:Ticketability.com Unleashes 2014 Usher Tickets for 1st Bank Center, American Airlines Center, Toyota Center, and Smoothie King Center Concerts 2Health News:Top 10 Best SEO Hosting: Justhost And Bluehost Are The Best Suppliers For Webmasters 2Health News:Center for Vascular Medicine Offers Genetic Testing For Personalized Vascular Care 2
... that combination asthma therapy, SYMBICORT leads to significant ... greater patient-reported satisfaction with asthma treatment, versus ... ,SYMBICORT is a recently approved, combination therapy ... in patients 12 years of age and older. ...
... imaging technique - magnetic resonance elastography (MRE) - is an ... ,The studies were conducted by a team of ... ,As part of one study, researchers conducted MRE examinations of ... ,The researchers found that MRE accurately detects ...
... bumps and bruises to contribute to a hostile ... harms another individual, through the manipulation of ... significant a concern for adolescent psychosocial development and ... Montclair State University and her colleagues from the ...
... joined forces with Canadian biotech company GangaGen Life Sciences ... food poisoning . ,They are engaging in ... control of Campylobacter the commonest cause of infectious ... the Health Protection Agency. Campylobacters are found in poultry ...
... Alzheimers one more breakthrough has been achieved. Scientists in New ... of mice using a magnetic stimulus in the region ... at the American Academy for Neuroscience conference. If proven, the ... Alzheimers disease, if not a cure. ,Experts ...
... A new study has found that obese patients with asthma ... those who are not overweight . ,The study ... Fernando Holguin and colleagues at Emory University. ,As ... than 3,000 adults by examining a data from the four-state ...
Cached Medicine News:Health News:Combo Therapy may Be Highly Beneficial in Asthma Control 2Health News:Psychological Bullying Hits Just as Hard 2Health News:Experts to Develop New Weapons Against Food Poisoning 2Health News:Experts to Develop New Weapons Against Food Poisoning 3Health News:Magnets to the rescue of Alzheimers patients 2Health News:Obesity Might Lead to Severe Persistent Asthma Attacks: Study 2
... Detect™ IgM Capture ELISA is for the ... WNV recombinant antigens (WNRA) in serum as ... of West Nile virus infection in patients ... results must be confirmed by Plaque Reduction ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: